XXIX CONGRESSO NAZIONALE IMI - NAPOLI, 29-30 SETTEMBRE E 1 OTTOBRE 2023

La quota di iscrizione include: accesso alle sessioni scientifiche, n. 2 light lunch, possibilità di ottenere i crediti ECM e attestato di partecipazione.

Categoria	Importo
Medici Soci IMI	€ 300.00
Medici non Soci IMI	€ 350.00
Specializzandi, non Medici	€ 150.00

* E' prevista l'iscrizione giornaliera per un importo di € 150.00.

La Segreteria confermerà via email le iscrizioni regolarmente pervenute. Si raccomanda quindi di inserire una e-mail valida, al fine di confermare correttamente l'iscrizione.
Le iscrizioni risultanti prive del pagamento non saranno prese in considerazione.
Non sono previsti rimborsi per cancellazioni.

ABSTRACT BOOK

POSTER SESSION

MODALITA' D'ISCRIZIONE

SEDE CONGRESSUALE

CONTATTI

Facebook

Twitter

Tumblr

Send by email

Share in Reddit

P101	Association of miR-146a-5p and miR-21-5p with prognostic features in melanoma subtypes Federico Venturi et al.
P102	Is MC1R-risk score a useful tool to evaluate the impact of MC1R SNPs on melanoma risk? Debora Tonello et al
P103	CUTANEOUS MELANOMA IN OLDER AND ELDERLY PATIENTS Alessandra Buja et al.
P104	Evaluation of a training course for general practitioners within the Melanoma Multimedia Education project of the Italian Melanoma Intergroup Federica Zamagni et al.

P202	Implications of dermoscopy in melanoma diagnosis: a clinical and medicolegal perspective. Andrea Michelerio et al.
P203	Multiple primary melanoma in patients with a previuous diagnosis of coutaneous melanoma: Incidence and type. Marco Menchini et al.
P204	Dermoscopy of cutaneous sebaceous carcinomas. Francesco Savoia et al.
P205	How to reach the diagnosis of melanoma? The importance of Skin Self-examination. An observational retrospective cohort-study of 711 patients with melanoma. Stefania Barruscotti et al.

P301	miR-214 as a driver of hyperpigmentation and therapy resistance in cutaneous melanoma Elena Andreucci et al.
P302	A newly discovered oncomiRs miR-4443-miR-4488/nestin axis governs the migratory and invasive phenotypes of resistant melanoma cells Lugi Fattore et al.
P303	Changes in peripheral and local tumor immunity after cemiplimab treatment early describe clinical outcomes in patients with cutaneous squamous cell carcinoma Anna Rita Amato et al.
P304	Sex differences in stage II cutaneous melanoma: the impact on survival outcomes. Ida Taglialatela et al.
P305	Prediction of the recurrence risk in stage IB-IIC cutaneous melanoma through artificial intelligence (AI) techniques on hematoxylin-eosin stain (H&E) images. Maria Colomba Comes et al.
P306	Locally-recurrent cutaneous squamous cell carcinoma lesions of head and neck: a case-control study based on genetic analysis. Maria Colombino et al.
P307	The interplay between miR-579-3p and microphthalmia-associated transcription factor (mitf) controls melanoma progression and resistance to targeted therapies. Domenico Liguoro et al.
P308	Exploring biomarkers of response for combination therapy with pembrolizumab and lenvatinib in metastatic melanoma resistant to anti-PD1 inhibitor. Roberta Di Fonte et al.
P309	A multiparameter liquid biopsy-based approach allows longitudinal tracking of cutaneous melanoma dynamics and early resistance to treatment. Maria Chiara Scaini et al.
P310	Tumor infiltrating lymphocytes recognition in primary melanoma by deep learning convolutional neural network. Filippo Ugolini et al.

P401	Electrochemotherapy: experience from an International Network for Sharing Practice on Electrochemotherapy center located in Mirano (Venice). Barbara Silvestri et al.
P402	Treatment of lentigo maligna with Mohs micrographic surgery and micrographically controlled staged excision: a two-center experience. Federica Scarfì et al.
P403	Isolated limb perfusion is still a choice? Bianca Taglione et al.
P404	Use of quantitative FLuorescence in systemAtic reSearcH of first NOn-sentinel lymph noDE in melanoma sentinel lymph node biopsy (FLASH-NODE Project): preliminary data of a feasibility study. Marco Clementi et al.
P405	Identifying High-Risk features and Improving Follow-up Strategies in Thin Melanoma: A Retrospective Cohort Study . Antonella Vecchiato et al.
P406	Isolated limb perfusion for locally advanced melanoma in the era of Targeted Therapies and Immunotherapy. Marco Rastrelli et al.
P407	Treatment and outcome of patients with melanoma and positive sentinel lymph node after MSLT-II, DeCOG and adjuvants trial. Serena Sestini et al.

P501	Cemiplimab in ultra-octogenarian patients with cutaneous Squamous Cell Carcinoma: the real-life experience of a tertiary referral center. Nerina Denaro et al.
P502	Lepto-Meningeal metastases in the modern era of melanoma treatment. A mono-institutional experience. Luigi Cerbone et al.
P503	The prognostic role of FDG PET/CT in patients with advanced cutaneous squamous cell carcinoma submitted to cemiplimab immunotherapy: a single-center retrospective study. Luca Filippi et al.
P504	Efficacy, tolerability, and quality of life (QoL) evaluation in six patients affected by Gorlin-Goltz syndrome and treated with Vismodegib 150mg/die: a retrospective monocentric cohort analysis. Biagio Scotti et al.
P505	Basal cell carcinomas’ histological subtypes and relative response to Vismodegib in six patients diagnosed with Gorlin-Goltz syndrome. Biagio Scotti et al.
P506	Evaluation of predictive factors in patients with advanced melanoma treated with immune checkpoint inhibitors in a real-world population. Stefano Poletto et al.
P507	A multidisciplinary characterization of immune-checkpoint inhibitor-related pneumonitis to improve its clinical management. Maura Colucci et al.
P508	Unveiling the immunological landscape of resected stage III/IV Melanoma patients treated with personalized dendritic cells vaccination in a phase II randomized trial. Laura Ridolfi et al.
P509	Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. Martina Merli et al.
P510	Adjuvant treatment in melanoma stage III patients: effects on disease relapse and prognosis. A Real world studio/data. Jacopo Pigozzo et al.
P511	Regulation of immune system gene expression in cSCC treated with immunotherapy: real life data of responders/non responders patients. Gabriella Suarato et al.
P512	Real-life outcomes of adjuvant therapy in melanoma: a single-center experience. Gabriele Roccuzzo et al.
P513	Obesity and immune-checkpoint inhibitors in advanced melanoma: A meta-analysis of survival outcomes from clinical studies. Gabriele Roccuzzo et al.
P514	A retrospective observational multicenter study on cutaneous adverse events induced by Cemiplimab. Matelda Medri et al.
P515	Tebentafusp in metastatic uveal melanoma patients (mUM): Veneto Institute of Oncology experience. Luisa Piccin et al.
P516	Effectiveness of dabrafenib plus trametinib in melanoma stage III adjuvant setting: results from the first interim analysis of the observational Italian study MADAM. Pietro Quaglino et al.